Ferring Pharmaceuticals Ltd
Budget
€25 — €0
EP Access
0
accredited persons
Staff
1
0.1 FTE
EU Grants
None
Mission & Goals
Ferring is a family-owned, research-driven specialty biopharmaceutical group committed to helping people build healthy families and live better lives. A world leader in reproductive medicine and maternal health, we have been developing for over 50 years treatments for mothers and babies, applying innovation in fertility, obstetrics and gynecology to ensure every potential parent has the best opportunity to build a family. Ferring is the only pharmaceutical company with a portfolio of products spanning the full spectrum from conception to birth, and we are committed to researching and developing new medicines in areas of high unmet need, including fertility and diseases of pregnancy e.g. recurrent pregnancy loss, preterm birth and post-partum haemorrhage. We are also specialised in gastroenterology and urology, and pioneering research of breakthrough medicines like gene therapies for specific types of cancers or microbiome-based therapies against serious bacterial infections.
EU Legislative Interests
Ferring is interested in all EU initiatives pertaining to public health, pharmaceutical policy and industrial policy. Recent files and initiatives of particular interest include amongst others: the ongoing review of the EU pharmaceutical legislation (with special attention to the ATMP Regulation), the set-up of the new European joint HTA system, or the EU’s work against the threat of Anti-Microbial Resistance (AMR). From a general point of view, we also have a major interest in all actions and initiatives under way at the EU level that may help advance better access to medicines for patients across Europe, bolster increased pharmaceutical research and development, provide greater and better incentives for pharmaceutical innovators like Ferring. We are also interested in and supportive of the European Union’s work (e.g. via the European Pillar of Social Rights) to build a fairer and more inclusive social Europe in which all individuals desiring to become parents have the opportunity to build a family.
Communication Activities
Ferring is regularly responding to various EU consultations of relevance to the topics outlined in the preceding section e.g. the Sept-Dec 2021 Public Consultation on the Revision of the EU General Pharmaceutical Legislation (see: https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12963-Revision-of-the-EU-general-pharmaceuticals-legislation/public-consultation_en) or the Feb-Mar 2022 Call for Evidence on Antimicrobial Resistance (see: https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/13322-Antimicrobial-resistance-recommendation-for-greater-action/F2940097_en)
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Ferring is a corporate member of EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org)
Organisation Members
Ferring is not a membership organisation, nor has any affiliated networks or associations.
Additional Information
Ferring conducted the preparation and submission of this entry in full consistency with the September 2021 Transparency Register Implementation Guidelines, as well as the most current guidance received from the major European trade bodies representing the pharmaceutical sector.
Commissioner Meetings
No recorded meetings with EU commissioners.